SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment.


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 26 03 2020
accepted: 14 04 2020
pubmed: 21 4 2020
medline: 19 6 2020
entrez: 21 4 2020
Statut: ppublish

Résumé

The new coronavirus outbreak is an ongoing pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus SARS-Cov-2 belongs to the subfamily of β-coronaviruses and shares 79.5% of the genetic sequence of SARS-CoV, the causative agent of the epidemic that started in 2002 and ended in 2004. Considering the clinical impact of the new outbreak, it is highly important to study the potential responses of the human immune system during the SARS-CoV-2 infection as well as the role of virus-specific T cells and by B-lymphocytes. Moreover, specific data on the production of IgG and IgM is crucial to allow the rapid identification of the infection. In this paper we also described the importance of sensitive and specific rapid test for SARS-CoV-2. Indeed, this test represents an important immunological tool aimed at identifying the precise phase of the infection in order to undertake a more appropriate pharmacological treatment. Lastly, we provided an overview of pharmacological treatments aimed to reduce inflammatory processes underlying the infection and the need for the discovery of a new vaccine against SARS-CoV-2.

Identifiants

pubmed: 32311668
pii: S1567-5769(20)30930-9
doi: 10.1016/j.intimp.2020.106519
pmc: PMC7161502
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antibodies, Viral 0
COVID-19 Vaccines 0
Viral Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106519

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Gabriella di Mauro (G)

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Regional Centre of Pharmacovigilance, Campania Region, Naples, Italy. Electronic address: gabriella.dimauro@unicampania.it.

Cristina Scavone (C)

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Regional Centre of Pharmacovigilance, Campania Region, Naples, Italy.

Concetta Rafaniello (C)

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Regional Centre of Pharmacovigilance, Campania Region, Naples, Italy.

Francesco Rossi (F)

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Regional Centre of Pharmacovigilance, Campania Region, Naples, Italy.

Annalisa Capuano (A)

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Regional Centre of Pharmacovigilance, Campania Region, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH